Rabies Vaccine Cipla 2,5 IU Lyophilised powder for reconstitution
PDF Leaflet Revision Date: 12 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of rabies in all age groups.
Dosage (summary)
Pre-exposure: 3 doses (1 mL IM) on days 0, 7, 21/28. Post-exposure: 5 doses (1 mL IM) on days 0, 3, 7, 14, 28.
Special Populations
- Immunocompromised
- Patients with bleeding disorders
Pregnancy & Breastfeeding
Use in pregnancy and breastfeeding should weigh benefits against risks; post-exposure prophylaxis is not contraindicated.
Key Drug Interactions
- Corticosteroids
- Chloroquine
- Immunosuppressive treatments
Contraindications
- Severe reaction to vaccine components
- Fever or acute illness
Common side effects
- Injection site reactions
- Fever
- Headache
- Nausea
Counselling Points
- Administer immediately after exposure
- Monitor for allergic reactions
- Do not inject into blood vessels
Serious warnings
- Anaphylactic reactions possible
- Intradermal route requires trained personnel
Important Disclaimer
The Rabies Vaccine Cipla 2,5 IU Lyophilised powder for reconstitution professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
